CCM
PBE icon

Coldstream Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Coldstream Capital Management’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-228
Closed -$14.5K – 2676
2025
Q1 		$14.5K Buy
+228
New +$15.3K ﹤0.01% 2242

Other funds holding PBE

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Coldstream Capital Management's PBE Position: Q2 2025 in Review

Coldstream Capital Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2025, closing a stake of 228 shares — an estimated $14.5K sold.

Coldstream Capital Management first reported a position in PBE in Q1 2025 and held it in 1 quarter. The position peaked at $14.5K in Q1 2025. 94 funds tracked by Wall St. Rank hold PBE as of Q2 2025.

  • Coldstream Capital Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 228 Invesco Biotechnology & Genome ETF shares in Q2 2025, an estimated $14.5K.
  • Coldstream Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Invesco Biotechnology & Genome ETF position peaked at $14.5K in Q1 2025.
  • 94 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.